Wolverine 20 — BPC-157 / TB-500 Composite
Dual-Peptide Recovery Research Blend · 20mg Research Vial
Available Formats
Vial
Lyophilised powder vial containing both compounds at a 1:1 ratio. Full flexibility in reconstitution.
Cartridge (Reusable Pen)
Pre-filled replacement cartridge compatible with standard reusable research pens. Pen sold separately.
Disposable Pen
Fully pre-loaded, self-contained research pen. Ready to use directly from packaging.
Compound Overview
The TR-2 Composite combines two independently studied research peptides into a single preparation at a 1:1 ratio:
BPC-157 (Body Protection Compound-157): A synthetic pentadecapeptide (15 amino acids) derived from a partial sequence of human gastric juice protein. BPC-157 has been the subject of extensive preclinical research, with over 100 published studies examining its interactions with nitric oxide (NO) systems, growth factor signalling (including VEGF, EGF, and FGF pathways), and the FAK-paxillin pathway involved in cell migration (Sikiric et al., 2018).
TB-500 (Thymosin Beta-4 Fragment 17-23): A synthetic heptapeptide fragment of Thymosin Beta-4, a 43-amino-acid peptide that functions as a major actin-sequestering protein. The TB-500 fragment contains the actin-binding domain (LKKTETQ) and has been studied in preclinical models for its role in cytoskeletal dynamics, cell motility, and extracellular matrix interactions (Goldstein et al., 2005).
Published Research
- Sikiric P et al. (2018) — Current Pharmaceutical Design, 24(18): 1952-1962. Comprehensive review of BPC-157 preclinical research across multiple organ systems and signalling pathways.
- Goldstein AL et al. (2005) — Expert Opinion on Biological Therapy, 5(8): 1053-1069. Review of Thymosin Beta-4 biology, actin-binding properties, and preclinical research applications.
Note: Citations are provided for reference purposes only. BioCompounds UK does not make therapeutic claims.
Structural & Chemical Data
| Compound Class | Dual-peptide research composite |
| Components | BPC-157 (10mg) + TB-500 (10mg) |
| Purity | >99% verified by HPLC (per component) |
| Form | Lyophilised powder (vial) / Pre-filled solution (cartridge & pen) |
| Quantity | 20mg per unit (10mg + 10mg) |
| Solubility | Sterile water / PBS |
| Storage (Dry) | -20 C |
| Storage (Reconstituted) | 2-8 C, use within 4 weeks |
Regulatory & Usage Notice
This product is supplied strictly as a research-grade reference compound for in-vitro laboratory investigation only. It is not approved, intended, or marketed for human or veterinary administration, diagnostic purposes, or therapeutic application. Purchasers must be qualified researchers aged 18+ and agree to handle all compounds in accordance with applicable regulations and good laboratory practice (GLP). BioCompounds UK makes no therapeutic claims regarding this or any compound in its catalogue.
Great